Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Breastfeeding support lacking in U.S. hospitals and birth centers

Many birth facilities in the United States are not providing maternity care that is fully supportive of breastfeeding, according to a study in today's Morbidity and Mortality Weekly Reports (MMWR), a publication of the Centers for Disease Control and Prevention.

15 Jun 2008

Evolution may have lumbered humans with allergy problems

Scientists funded by the Biotechnology and Biological Sciences Research Council (BBSRC) have discovered how evolution may have lumbered humans with allergy problems.

15 Jun 2008

Lupus more severe in patients with ancestry from southern Europe

Systemic lupus erythematosus (SLE) patients with a higher percentage of ancestry from southern Europe have more severe disease manifestations, according to new research presented today at EULAR 2008, the Annual Congress of the European League Against Rheumatism in Paris, France.

11 Jun 2008

Compugen announces discovery of novel drug targets for cancer antibody therapeutics

Compugen Ltd. announced today the discovery of more than ten novel targets of antibody therapy for various types of solid and hematopoietic cancer.

11 Jun 2008

Maxygen receives approval for trial of factor VIIa in UK

Maxygen, Inc. today announced that it has filed a Clinical Trial Authorization (CTA) and received the necessary approvals in the United Kingdom to initiate a first-in-human Phase I trial of MAXY-VII in hemophilia patients.

11 Jun 2008

Oxygen-rich lifesaving efforts pose risk for respiratory infections

Each year, thousands of premature infants battle to breathe. Thanks to life-saving interventions developed in the past couple decades - steroids given to their mothers to stall pre-term labor, mechanical ventilation, air enriched with extra oxygen, and surfactant, a crucial wetting agent that makes breathing less work - most of these newborns survive with enough lung function to grow and go home.

11 Jun 2008

Scientists identify a key regulator of DNA mutations

As a general rule, your DNA is not something you want rearranged. But there are exceptions - especially when it comes to fighting infections. Since the number of microbes in the world far surpasses the amount of human DNA dedicated to combat them, specialized cells in the immune system have adopted an ingenious, if potentially disastrous, strategy for making antibodies. These cells, called B lymphocytes, intentionally mutate their own DNA to ward off invaders they have never seen before.

9 Jun 2008

Role of breastfeeding in preventing infant death, HIV infection in developing countries

In many poor countries, mothers with HIV face a stark choice: to nurse their infants, and risk passing on HIV through their breast milk - or to formula feed, and deprive their infants of much of the natural immunity needed to protect against fatal diseases of early infancy. Now, two studies supported by the National Institutes of Health offer insights into preventing early death and HIV infection among breastfeeding infants of mothers with HIV in these countries.

5 Jun 2008

Bird flu hits the UK and the U.S.

Tests currently being conducted will determine just how virulent the H7 strain is and in the meantime a temporary inner control zone of 3km has been set up around the farm along with a 10km outer zone.

5 Jun 2008

CSL Behring study shows extended half-life recombinant VIIa leads to longer biologic activity

CSL Behring today presented results of a pre-clinical study that not only demonstrates the feasibility of genetically fusing factor VIIa to human albumin, but that this therapeutic protein with a prolonged half-life can lead to a longer biologic effect.

3 Jun 2008

ThromboGenics and BioInvent report positive results for anti-PlGF cancer therapeutic TB-403

ThromboGenics NV and co-development partner BioInvent International AB today reported that the results from the first Phase l study of novel anti-cancer agent TB-403 showed that it is safe and well tolerated, with pharmacokinetic properties enabling it to be developed for the treatment of cancer

3 Jun 2008

Probiotics provide hay fever hope

With the peak grass pollen season approaching, scientists can reveal that a daily dose of probiotic can change the immune status of people with hay fever.

2 Jun 2008

Arana and Greenovation in anti-cancer co-development deal

Arana Therapeutics Limited and Germany-based greenovation Biotech GmbH have entered into a collaborative agreement to develop next generation anti-cancer antibodies.

2 Jun 2008

New breast cancer drug combo shrinks aggressive tumours

An international trial of a new breast cancer drug has shown the drug is able to shrink tumours caused by one of the most aggressive forms of the disease.

2 Jun 2008

Peregrine Pharmaceuticals updates on Bavituximab breast cancer study

Peregrine Pharmaceuticals, Inc. has announced that results from a Phase I clinical trial of its lead anti-phosphatidylserine (anti-PS) antibody bavituximab in combination with chemotherapy in patients with advanced cancer were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting.

2 Jun 2008

Medarex announces preliminary data for investigational anti-PD-1 antibody

Medarex, Inc. has announced preliminary data from an ongoing Phase 1 study of MDX-1106 (ONO-4538: development code of Ono Pharmaceutical Co., Ltd.), a fully human anti-PD-1 antibody.

2 Jun 2008

Combination biotherapies safe, promising for melanoma patients

The combination of two different biotherapies may be beneficial for patients with inoperable melanoma, according to a University of Pittsburgh Cancer Institute (UPCI) study presented at the 44th annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

1 Jun 2008

Why do Finnish children have type 1 diabetes and allergic symptoms approximately five times more often than children in Russian Karelia?

High living standards and the life style connected to them seem to promote the development of autoimmune diseases and allergic symptoms. This has lead to the assumption that the immune system begins to overreact to the organism's own structures or to exogenous non-infectious proteins, i.e. allergens, when it does not have to work hard enough to protect the individual from infections.

28 May 2008

First patient enrolled in phase III study of Bevacizumab and Trastuzumab in early breast cancer

A new international study for women with HER2-positive breast cancer is open for enrollment. The pivotal BETH (BEvacizumab and Trastuzumab Adjuvant Therapy in HER2-positive Breast Cancer) study is a Phase III clinical research trial that is investigating the benefits of combining two monoclonal antibodies, the anti-angiogenic, bevacizumab (Avastin) and the targeted therapy trastuzumab (Herceptin), together with chemotherapy for the treatment of patients with early stage HER2-positive breast cancer.

27 May 2008

Intracellular antibody mops up mutant protein in Huntington's disease model

Scientists have created a tool for mopping up the clumps of mutant protein that drive neurodegeneration in Huntington's disease. Emory University researchers engineered a virus to make an intracellular antibody or "intrabody" against huntingtin, the protein whose mutant forms poison the brain cells of people with Huntington's.

26 May 2008